Disease · MONDO_0000481

cervical dystonia

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. cervical dystonia. Diseases, record MONDO_0000481. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0000481

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: cervical dystonia; Open Targets
Open Targets ID: MONDO_0000481; Open Targets
Other names: Autosomal dominant cervical dystonia, Autosomal dominant spasmodic torticollis, Loxia, Spasmodic torticollis, Torticollis, Wry neck; Open Targets
Disease Ontology: DOID:0050840; Disease Ontology
NCI Thesaurus: C85072; NCI Thesaurus
Orphanet: ORPHA:93962; Orphanet
Highest stage of its drugs: Approval, for 1 of its 14 drugs, from PMDA; Open Targets

Drugs14

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
RIMABOTULINUMTOXINB	CHEMBL1201569	Protein	Approval	PMDA	4	2	2	Drugs and targets
ONABOTULINUMTOXINA	CHEMBL1201574		Phase 3	ClinicalTrials.gov	17	17	8	Drugs and targets
BOTULINUM TOXIN TYPE A	CHEMBL4297862	Protein	Phase 3	ClinicalTrials.gov	11	11	4	Drugs and targets
ABOBOTULINUMTOXINA	CHEMBL2108570		Phase 3	ClinicalTrials.gov	3	3	2	Drugs and targets
DAXIBOTULINUMTOXINA	CHEMBL3707359		Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets
INCOBOTULINUMTOXINA	CHEMBL2108035		Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
PRABOTULINUMTOXIN A	CHEMBL4297229		Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
AMLODIPINE	CHEMBL1491	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
DRONABINOL	CHEMBL465	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
LEVETIRACETAM	CHEMBL1286	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 14

See all 14 drugs

Targets14

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
SNAP25	Synaptosomal-associated protein 25	7	Synaptosomal nerve-associated protein 25 (SNAP-25) hydrolytic enzyme; Synaptosomal nerve-associated protein 25 (SNAP-25) inhibitor; Synaptosomal nerve-associated protein 25 (SNAP-25) proteolytic enzyme	Phase 3	https://conductscience.org/library/genes/6616	Drugs and targets
CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1B	1	Voltage-gated N-type calcium channel alpha-1B subunit blocker	Phase 2	https://conductscience.org/library/genes/774	Drugs and targets
CACNA1C	Voltage-gated L-type calcium channel	1	Voltage-gated L-type calcium channel blocker	Phase 2	https://conductscience.org/library/genes/775	Drugs and targets
CACNA1D	Voltage-gated L-type calcium channel	1	Voltage-gated L-type calcium channel blocker	Phase 2	https://conductscience.org/library/genes/776	Drugs and targets
CACNA1F	Voltage-gated L-type calcium channel	1	Voltage-gated L-type calcium channel blocker	Phase 2	https://conductscience.org/library/genes/778	Drugs and targets
CACNA1S	Voltage-gated L-type calcium channel	1	Voltage-gated L-type calcium channel blocker	Phase 2	https://conductscience.org/library/genes/779	Drugs and targets
CNR1	Cannabinoid receptor 1	1	Cannabinoid CB1 receptor agonist	Phase 2	https://conductscience.org/library/genes/1268	Drugs and targets
GRIA1	Glutamate receptor ionotropic AMPA	1	Glutamate receptor ionotropic AMPA antagonist	Phase 1/2	https://conductscience.org/library/genes/2890	Drugs and targets
GRIA2	Glutamate receptor ionotropic AMPA	1	Glutamate receptor ionotropic AMPA antagonist	Phase 1/2	https://conductscience.org/library/genes/2891	Drugs and targets
GRIA3	Glutamate receptor ionotropic AMPA	1	Glutamate receptor ionotropic AMPA antagonist	Phase 1/2	https://conductscience.org/library/genes/2892	Drugs and targets

1 to 10 of 14

See all 14 targets

Trials26

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 12 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00702754	Open Label Safety/Immunogenicity Study of MYOBLOC (Neurobloc; Botulinum Toxin Type B) in Patients With Cervical Dystonia	Phase 4	502	2009-09-23	Cervical Dystonia	RIMABOTULINUMTOXINB	Its record names the disease	ClinicalTrials.gov
NCT01261611	Study Comparing Short Term Efficacy of Dysport and Dysport NG to Placebo, and to Assess Efficacy and Safety of Dysport NG of Subjects With Cervical Dystonia	Phase 3	382	2019-09-24	Cervical Dystonia	ABOBOTULINUMTOXINA	Its record names the disease	ClinicalTrials.gov
NCT00564681	Study to Evaluate Safety, Efficacy of Botulinum Toxin Type A in Patients With Cervical Dystonia	Phase 2	242	2012-12-11	Cervical Dystonia	ONABOTULINUMTOXINA	Its record names the disease	ClinicalTrials.gov
NCT00407030	IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Cervical Dystonia	Phase 3	233	2010-12-31	Cervical Dystonia	INCOBOTULINUMTOXINA	Its record names the disease	ClinicalTrials.gov
NCT00165776	Randomized, Double-Blind, Placebo-Controlled, Parallel, Group Dose-Response, Study of E2014 in Patients WIth Spasmodic Torticollis	Phase 2	133	2014-01-08	Cervical Dystonia, Spasmodic Torticollis	RIMABOTULINUMTOXINB	Its record names the disease	ClinicalTrials.gov
NCT01753336	Long Term Safety And Effectiveness Of Dysport® In Adults With Cervical Dystonia	Phase 3	112	2017-05-04	Cervical Dystonia	ONABOTULINUMTOXINA	Its record names the disease	ClinicalTrials.gov
NCT04849988	A Phase 2 Study to Evaluate the Safety and Efficacy of ABP-450 in the Treatment of Cervical Dystonia	Phase 2	61	2024-02-14	Cervical Dystonia	PRABOTULINUMTOXIN A	Its record names the disease	ClinicalTrials.gov
NCT04871451	Extension Study of ABP-19000 to Evaluate Safety and Efficacy of Repeat Treatments of ABP-450 in Cervical Dystonia	Phase 2	51	2024-08-22	Cervical Dystonia	PRABOTULINUMTOXIN A	Its record names the disease	ClinicalTrials.gov
NCT00015457	Amlodipine Plus Botulinum Toxin for Focal Dystonia	Phase 2	16	2013-04-01	Focal Dystonia	AMLODIPINE, ONABOTULINUMTOXINA	Its record names the disease	ClinicalTrials.gov
NCT01753349	Phase IV-Cervical Dystonia-INTEREST IN CD2		1,050		Cervical Dystonia	ABOBOTULINUMTOXINA, BOTULINUM TOXIN TYPE A	Its record names the disease	ClinicalTrials.gov

1 to 10 of 26

See all 26 trials

Comparisons in its trials1

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial
Amlodipine vs Placebo: serious adverse events	0 of 16	0 of 16	32	NCT00015457

Source Trial comparisons

Papers from its trials10

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
38386480	RESULT	1	PubMed
23779062	RESULT	1	PubMed
21764407	RESULT	1	PubMed
40439027	DERIVED	1	PubMed
38295339	DERIVED	1	PubMed
34316644	DERIVED	1	PubMed
32884828	DERIVED	1	PubMed
31478151	DERIVED	1	PubMed
30009213	DERIVED	1	PubMed
27653448	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0000481

GET https://conductscience.org/api/diseases/v1/MONDO_0000481/trials?page=2

API reference For AI assistants